No. S 354
Misuse of Drugs Act
(CHAPTER 185)
Misuse of Drugs Act
(Amendment of First, Third and
Fifth Schedules) Order 2019
In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:
Citation and commencement
1.  This Order is the Misuse of Drugs Act (Amendment of First, Third and Fifth Schedules) Order 2019 and comes into operation on 1 May 2019.
Amendment of First Schedule
2.  Part I of the First Schedule to the Misuse of Drugs Act is amended —
(a)by inserting, immediately after item (34) of paragraph 1, the following item:
(34A)(2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide (also known as Lisdexamphetamine or Lisdexamfetamine) and its stereoisomers”;
(b)by inserting, immediately after item (120) of paragraph 1, the following item:
(120A)4-Phenyl-N-(2-phenylethyl)piperidin-4-yl acetate (also known as 1-Phenethyl-4-phenyl-4-piperidinol acetate or PEPAP)”;
(c)by inserting, immediately after item (8) of paragraph 7, the following items:
(8AA)Cyclopropylfentanyl
(8AB)4-Fluorobutyrfentanyl (also known as para-Fluoro-butyrfentanyl or p-Fluoro-butyrfentanyl)
(8AC)2-Fluorofentanyl (also known as ortho-Fluorofentanyl)
(8AD)3-Fluorofentanyl (also known as meta-Fluorofentanyl)
(8AE)4-Fluorofentanyl (also known as para-Fluorofentanyl)”;
(d)by inserting, immediately after item (9) of paragraph 7, the following items:
(9A)Methoxyacetylfentanyl
(9B)4-Methoxybutyrfentanyl (also known as para-Methoxy-butyrfentanyl or p-Methoxy-butyrylfentanyl)”;
(e)by deleting item (11) of paragraph 7;
(f)by deleting the word “N-Ethylpentylone” in item (1C) of paragraph 16 and substituting the words “1-(2H-1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) or N-Ethylpentylone or N-Ethylnorpentylone or Ephylone”;
(g)by deleting item (1) of paragraph 18 and substituting the following items:
(1)N-(Adamant-1-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37)
(1AAA)N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group”;
(h)by inserting, immediately after the words “also known as” in item (2BA) of paragraph 18, the words “N‑(1‑Amino‑3,3‑dimethyl‑1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]‑1H‑indazole‑3‑carboxamide or”;
(i)by inserting, immediately after item (10) of paragraph 18, the following item:
(10AA)3,4-Dichloromethylphenidate and its dichloro positional isomers in the phenyl ring (also known as 3,4‑DCMP)”;
(j)by inserting, immediately after item (20A) of paragraph 18, the following item:
(20AA)1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as 5-Fluoro-cumyl-PICA) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group”;
(k)by deleting the word “MMB-FUBINACA” in item (28F) of paragraph 18 and substituting the words “Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate or MMB-FUBINACA or AMB-FUBINACA or FUB-AMB”;
(l)by inserting, immediately after the words “also known as” in item (31A) of paragraph 18, the words “1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide or”;
(m)by inserting, immediately after item (35) of paragraph 18, the following item:
(35A)Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate (also known as 5-Fluoro-SDB-005) and its fluoro positional isomers in the pentyl group”;
(n)by inserting, immediately after item (36A) of paragraph 18, the following item:
(36AA)Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (also known as SDB-005)”; and
(o)by deleting item (38AA) of paragraph 18.
Amendment of Third Schedule
3.  Paragraph 1 of Part I of the Third Schedule to the Misuse of Drugs Act is amended —
(a)by inserting, immediately below the item “Acetic anhydride also known as Acetic oxide”, the following item:
Alpha-phenylacetoacetamide also known as APAA”;
(b)by inserting, immediately below the item “4-Anilino-N-phenethylpiperidine also known as ANPP”, the following item:
3-(1,3-Benzodioxol-5-yl)-2-methyl-2-oxiranecarboxylic acid also known as 3,4-MDP-2-P methyl glycidic acid or PMK glycidic acid”; and
(c)by inserting, immediately below the item “Lysergic acid also known as 9,10-Didehydro-6-methylergoline-8β-carboxylic acid”, the following item:
Methyl 3-(1,3-benzodioxol-5-yl)-2-methyl-2-oxiranecarboxylate also known as 3,4-MDP-2-P methyl glycidate or PMK glycidate”.
Amendment of Fifth Schedule
4.  Paragraph 1 of the Fifth Schedule to the Misuse of Drugs Act is amended by deleting items (1) to (5) and substituting the following items:
 
“(1)5-(5-Fluoropentyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one (also known as 2-Cumyl-5-(5-fluoropentyl)-gamma-carbolin-1-one or 5-Fluoro-cumyl-PEGACLONE) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group
 
(2)2-(2-Phenylpropan-2-yl)-5-pentyl-pyrido[4,3-b]indol-1-one (also known as 2‐Cumyl‐5‐pentylgamma‐carbolin‐1‐one or cumyl PEGACLONE or SGT-151) and its phenylpropyl isomers”.
Made on 25 April 2019.
PANG KIN KEONG
Permanent Secretary,
Ministry of Home Affairs,
Singapore.
[MHA 112/2/0049; AG/LEGIS/SL/185/2015/2 Vol. 2]